Boehringer Ingelheim Pharmaceuticals as a “middle ground partner” is an interesting concept. I have written about BI in the past as being a company that could work some synergy with Peregrine. Peregrine, through Avid, is currently, and has been in a partnership with BI for a few years now.
BI has more to offer Peregrine than just worldwide manufacturing facilities, they also have a worldwide marketing web. BI, with its substantial presence in all regions, had revenues in 2012 of €14.7 billion.
“Boehringer Ingelheim is a research-driven group of companies. We are dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. The Boehringer Ingelheim Corporation currently has more than 46,000 employees and 140 affiliated companies spread around the globe.”
I would not at all be surprised if the current partnership with BI were to be expanded beyond manufacturing to regional marketing and other co-benefits.
Peregrine is now conducting a phase3 trial of bavituximab treating 2nd-line advanced NSCLC. The FDA has also just recently awarded bavi with a Fast Track designation. I’m expecting that Dr. Garnick has a strong chance of getting Peregrine an Accelerated Approval, AA, when this trial is opened for the early look-in.
I am also expecting a partnership(s) announcement by Peregrine. There’s no way to guess the timing of this type of announcement. Drug development takes years, but announcements happen in a moment.
Market Data 
Markets 
AI
